Clinical Trial Results:
Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement.
A double blind, parallel, dose-finding study in comparison with open label enoxaparin
(Study no. 150-CL-008)
Protocol for Phase 2B Study of YM150
Summary
|
|
EudraCT number |
2005-002457-41 |
Trial protocol |
AT CZ SK DE SE NO FI PT GR IT LT EE LV |
Global completion date |
07 Aug 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Sep 2016
|
First version publication date |
15 Sep 2016
|
Other versions |
|
Summary report(s) |
Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.